28% growth masks margin miss; profit growth trails sharply

₹697.2 Cr revenue confirmed; 28% YoY growth matches delivered result

Q1 delivered 11.6% EBITDA margin vs 12.5% prior year; miss by ~90-130 bps

PAT ₹35.1 Cr +4.5% YoY; growth lags revenue 28% growth by 530 bps; QoQ down 23.7%

CFO retreated to 15% growth guidance despite 28% Q1; hedging heavily on macro/geopolitical uncertainty

Core B2B EBITDA ₹85 Cr at 14% margin confirmed; signals underlying business healthier than consolidated 11.6%

Initially 15% growth guidance; on strong 28% Q1, management retreated citing 'volatility and uncertainty', stuck to 15% range. Profit growth concern (4.5% vs 28% revenue) signals execution risk.

Target 15% EBITDA margins pushed to 2-3 year horizon post-B2C exit; current 11.6% miss vs prior 12-13% guidance. Multiple dependencies: capacity utilization, B2C rationalization, input cost normalization.

Previously calibrated; now slowed to R&D-only spending post-expansion completion. Saudi Arabia still in early-stage exploratory phase, no timeline.

Expected by Dec 2026, not earlier; FY28 to see full-year benefit. Confirms near-term constraint persists.

Capacity utilization improving, low-margin business exits underway, pharma/aroma expansion planned. Pricing power confirmed but raw material volatility and freight headwinds offset. Next 2 years to show improvement.

Sales growing faster but difficult to predict. Market volatility, geopolitical uncertainty, freight spikes make quarterly forecasting hard. Sticking to 15% on annualized basis.

Yes, expecting same as base level. Exit of low-margin B2C business will push improvement over next 1-2 years.

₹2-3 Cr Q1 from textile products; small formulation plant (₹10-15 Cr investment). Ramp gradual. Future AHN/HPPC products possible.

Still in survey/feedstock allocation stage. No finalization yet. Will announce when decided. Geopolitical uncertainty but conviction intact.

Started few products Q1; compliance-heavy process. Target Q2-Q3 compliance completion. H2 potential ₹30-50 Cr. Steady state ramp over time.

Core B2B at 14-15% margins today. Target 15% consolidated post-exit once utilization optimizes. Two-year plan.

~10% volume growth; rest from pricing. Reflects commodity pass-through mechanics.

New products (NMMO, biosurfactants, enzymes, trace minerals); pharma ₹50+ Cr; lower-EO formulations with higher non-EO content. Healthy growth despite lean season.

Exit consumer B2C only; keeping institutional cleaning products (more profitable). ~₹50 Cr debt in segment. Exit releases 2-3% EBITDA margin.

EBITDA per kilo better metric. Freight volatility, raw material spikes (phenol ₹5 Cr hit), Saudi Arabia seeding costs pressure margins. Focus on EBITDA per kg, consolidate toward 15% plus.

FY27 stick to 15% growth; FY28 should be better with full-year EO availability, pharma ramp, and capacity utilization improvements.

Net debt ₹248 Cr (down from ₹280 Cr in March). Interest higher because prior capex interest was capitalized; now P&L impact. Going forward ₹9-10 Cr run rate.

Andheri office in Unitop's name; assets revalued 5 years ago at market price. Profit element only ₹3.2 Cr in Q1 other income despite ₹10.5 Cr sale price.

Continuing investments. Scaling Rossari >2x over 4 years requires market presence. Will not cut seeding to boost near-term EBITDA.

EO capacity ~100% utilized. MDEA continuous plant major investment ramping next 12 months; should see higher margins. EO pricing controlled (sole supplier); margin gain depends on product mix at time of supply.

Initially 15% FY27 minimum; Q1 beat at 28% but management hedged on macro/geopolitical volatility. Sticking to 15% annualized.

Q1 delivered 11.6%, below 12-13% range. Contingent on B2C exit (~₹50 Cr debt), capacity utilization normalization, and input cost stabilization.

Large capex cycle completed. Focus now on utilization. Saudi Arabia in early exploratory stage; no timeline given.

Phenol price spike caused ₹5 Cr loss in Q1; freight costs volatile tied to geopolitical/shipping disruptions. Pricing power exists but lag in pass-through creates margin pressure.

Q1 delivered 11.6% vs 12-13% guidance; B2C drag persists. 2-3 year timeline to reach 15% target contingent on exit and utilization. Risk of further delays.

PAT +4.5% YoY vs revenue +28%; QoQ PAT down 23.7%. Profit conversion severely weak. Suggests operational leverage not materializing and cost inflation uncontrolled.

EO shortage limits growth in core ethoxylation business; supply expected only by Dec 2026. Until then, growth levers limited to non-EO products and new segments (pharma, aroma).

Thailand plant yielded only ₹2-3 Cr Q1 from ₹10-15 Cr investment. Saudi Arabia still in survey/early stage despite being strategic; geopolitical risk and 1.5-year ramp-up post-announcement.